Mereo BioPharma Group PLC（MREO）の株価予測MREOMereo BioPharma Group PLC

Alphio's MREO stock price prediction model matches the current Mereo BioPharma Group PLC tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.28 (-0.85%). The 1-week path is $0.29 (+2.43%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Mereo BioPharma is not a good buy right now. The current price is $0.283, which is significantly lower than its 52-week high of $2.37, indicating a steep decline of 84.01% over the past year. Additionally, the stock has an RSI of 39.354, suggesting it is nearing oversold territory but still lacks strong upward momentum. The company's financials show a gross margin of 73.60% in Q2 2025, but it also reported a net income loss of $14.6 million in the same quarter, raising concerns about profitability. The downgrade by JP Morgan due to regulatory uncertainties surrounding setrusumab further diminishes investor confidence, making this a risky investment.

Mereo BioPharma Group PLC (MREO) last closed at $0.283, gaining +0.93%. These facts feed the 1-day and 1-week MREO price prediction above.